J
Julie M. Vose
Researcher at University of Nebraska Medical Center
Publications - 569
Citations - 51589
Julie M. Vose is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 97, co-authored 541 publications receiving 46915 citations. Previous affiliations of Julie M. Vose include Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
NCCN guidelines® insights chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured updates to the NCCN guidelines
William G. Wierda,Andrew D. Zelenetz,Leo I. Gordon,Jeremy S. Abramson,Ranjana H. Advani,C. Babis Andreadis,Nancy L. Bartlett,John C. Byrd,Paolo Caimi,Luis Fayad,Richard I. Fisher,Martha Glenn,Thomas M. Habermann,Nancy L. Harris,Francisco J. Hernandez-Ilizaliturri,Richard T. Hoppe,Steven M. Horwitz,Mark S. Kaminski,Chris R. Kelsey,Youn H. Kim,Susan Krivacic,Ann S. LaCasce,Michael Gary Martin,Auayporn Nademanee,Pierluigi Porcu,Oliver W. Press,Rachel Rabinovitch,Nishitha Reddy,Erin Reid,Kenneth B. Roberts,Ayman Saad,Erin D Snyder,Lubomir Sokol,Lode J. Swinnen,Julie M. Vose,Joachim Yahalom,Mary A. Dwyer,Hema Sundar +37 more
TL;DR: Important updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for CLL/ SLL for the treatment of patients with newly diagnosed or relapsed/refractory C LL/SLL are highlighted.
Journal Article
Cardiopulmonary function and autologous bone marrow transplantation: Results and predictive value for respiratory failure and mortality
Bharat Jain,Anthony A. Floreani,James R. Anderson,Julie M. Vose,Richard A. Robbins,S. I. Rennard,Joseph H. Sisson +6 more
TL;DR: ETT and EF performed prior to transplant in lymphoma patients undergoing autologous transplant do not predict for either respiratory failure or short-term mortality, and these findings may be due to the rather low incidence of respiratory failure and low early mortality seen in the patient population.
Journal ArticleDOI
Phase I/II Trial of Bortezomib + CHOP-Rituximab in Diffuse Large B Cell (DLBCL) and Mantle Cell Lymphoma (MCL): Phase I Results.
John P. Leonard,Richard R. Furman,Ying-Kuen K. Cheung,Eric J. Feldman,Hearn Jay Cho,Julie M. Vose,Gwen Nichols,Patricia Glynn,Maureen A. Joyce,Jamie C. Ketas,Jia Ruan,John F. Carew,Ruben Niesvizky,Ann S. LaCasce,Amy Chadburn,Ethel Cesarman,Morton Coleman +16 more
TL;DR: Bortezomib can be administered with acceptable toxicity in conjunction with CHOP-R chemotherapy in patients with DLBCL and MCL, and preliminary findings with the combination regimen in this adverse prognosis group of patients are encouraging.
Journal ArticleDOI
Comparison of monocyte-dependent T cell inhibitory activity in GM-CSF vs G-CSF mobilized PSC products
Ana G. Ageitos,Michelle L. Varney,P. J. Bierman,Julie M. Vose,Phyllis I. Warkentin,James E. Talmadge +5 more
TL;DR: The immune properties of peripheral blood stem cell (PSC) products mobilized with different hematopoietic growth factors (HGFs) as well as apheresis products and peripheral blood leukocytes from normal individuals are compared.
Journal ArticleDOI
The prognostic significance of lymphopenia in peripheral T-cell and natural killer/T-cell lymphomas: A study of 826 cases from the International Peripheral T-cell Lymphoma Project
Zdravko Mitrović,Zdravko Mitrović,Anamarija M. Perry,Junji Suzumiya,James O. Armitage,Wing Y. Au,Bertrand Coiffier,Harald Holte,Elaine S. Jaffe,Emili Monserrat,Sandeep K. Rajan,Kerry J. Savage,Kensei Tobinai,Julie M. Vose,Dennis D. Weisenburger +14 more
TL;DR: Lymphopenia was identified as a new adverse prognostic factor in the lymphoma type of adult T‐cell leukemia/lymphoma (ATLL), with a 2‐year OS of 15% versus 40% for those without lymphopenia, independently associated with an inferior overall survival.